Hypohidrotic Ectodermal Dysplasia News and Research

RSS

Researchers who study HED identify mechanism that may be disrupted in male pattern baldness

It is almost axiomatic in medicine that the study of rare disorders informs the understanding of more common, widespread ailments.

8 Jun 2017

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company's novel, proprietary, recombinant protein.

13 Jun 2012

Study confirms defect in sweat gland function as disease biomarker for XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia.

9 Nov 2010

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

10 Sep 2010

Hypohidrotic Ectodermal Dysplasia News and Research

Researchers who study HED identify mechanism that may be disrupted in male pattern baldness

FDA awards research grants to boost product development for patients with rare diseases

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

FDA grants Fast Track designation to Edimer’s EDI200 for treatment of XLHED

Study confirms defect in sweat gland function as disease biomarker for XLHED

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Latest News